Burrows Scott L
- SEC CIK
- 0001853327
In the past year, 8 open-market sale filings worth $6.86M and no purchases.
Current role at each company
- SYRE Spyre Therapeutics, Inc.Chief Financial Officeras of Sep 3, 2026
- ARQT Arcutis Biotherapeutics, Inc.Chief Financial Officeras of Mar 8, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $6.86M
- 8 filings
- Net
- −$6.86M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Burrows Scott L as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
SYRE Spyre Therapeutics, Inc.
Chief Financial Officer10 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 5, 2024 (view filing) | Sep 3 | 2 days | Burrows Scott LChief Financial Officer | SSale | −18.5K | $28.17 | −$522.0K | −13.7%116.4K after | |
| Sep 3, 2025 (view filing) | Sep 2 | 1 day | Burrows Scott LChief Financial Officer | SSale | −18.4K | $16.26 | −$299.6K | −15.8%98.0K after | |
| Mar 3, 2026 (view filing) | Mar 3 | Same day | Burrows Scott LChief Financial Officer | SSale | −2.50K | $40.65 | −$101.6K | −2.5%98.0K after | 2 lots10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Burrows Scott LChief Financial Officer | SSale | −7.50K | $49.34 | −$370.1K | −7.1%98.0K after | 2 lots10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Burrows Scott LChief Financial Officer | SSale | −12.5K | $71.37 | −$892.1K | −11.3%98.0K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Burrows Scott LChief Financial Officer | SSale | −7.50K | $71.06 | −$532.9K | −7.1%98.0K after | 3 lots10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Burrows Scott LChief Financial Officer | SSale | −15.0K | $87.13 | −$1.31M | −13.3%98.0K after | 2 lots |
| Jul 2, 2026 (view filing)9:33 PM ET | Jul 1 | 1 day | Burrows Scott LChief Financial Officer | SSale | −7.50K | $87.74 | −$658.0K | −7.1%98.0K after | 2 lots10b5-1 |
| Aug 5, 2026 (view filing)9:32 PM ET | Aug 3 | 2 days | Burrows Scott LChief Financial Officer | SSale | −7.50K | $95.57 | −$716.8K | −7.1%98.0K after | 3 lots10b5-1 |
| Sep 3, 2026 (view filing)9:33 PM ET | Sep 1-2 | 2 days | Burrows Scott LChief Financial Officer | SSale | −25.7K | $88.75 | −$2.28M | −24.4%79.8K after | 5 lots10b5-1 |
ARQT Arcutis Biotherapeutics, Inc.
Chief Financial Officer5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 (view filing) | Dec 27 | 1 day | Burrows Scott LChief Financial Officer | SSale | −12.6K | $20.07 | −$252.1K | −35.6%22.7K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Burrows Scott LChief Financial Officer | SSale | −420 | $17.75 | −$7.46K | −1.9%22.3K after | |
| Mar 7, 2022 (view filing) | Mar 4-7 | 3 days | Burrows Scott LChief Financial Officer | SSale | −303 | $16.85 | −$5.10K | −0.9%35.3K after | 2 lots |
| Mar 2, 2023 (view filing) | Feb 28-Mar 2 | 2 days | Burrows Scott LChief Financial Officer | SSale | −1.85K | $15.91 | −$29.4K | −4.6%38.4K after | 3 lots |
| Mar 8, 2023 (view filing) | Mar 6 | 2 days | Burrows Scott LChief Financial Officer | SSale | −291 | $15.26 | −$4.44K | −0.5%59.1K after |